JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China
publication date: Sep 14, 2023
Shanghai JW Therapeutics will add two additional candidates for China to its T cell-based therapeutics collaboration with Boston’s 2seventy bio: a T-cell receptor molecule for solid tumors and a CAR T candidate for autoimmune diseases. The collaboration, announced last year, was set up to advance 2seventy products into clinical trials quickly. One of the two original products, a MAGE-A4 solid tumor program, is expected to start an investigator study later this year, which is faster than expected. JW was formed by Wuxi Apptec and Seattle’s Juno Therapeutics to bring cell therapies to China. More details....
Stock Symbols: (HK: 2126) (Nasdaq: TSVT)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.